Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab

被引：13

作者：

Hiraoka, Atsushi ^{[1
]}

Kumada, Takashi ^{[2
]}

Tada, Toshifumi ^{[3
]}

Hirooka, Masashi ^{[4
]}

Kariyama, Kazuya ^{[5
]}

Tani, Joji ^{[6
]}

Atsukawa, Masanori ^{[7
]}

Takaguchi, Koichi ^{[8
]}

Itobayashi, Ei ^{[9
]}

Fukunishi, Shinya ^{[10
]}

Tsuji, Kunihiko ^{[11
]}

Ishikawa, Toru ^{[12
]}

Tajiri, Kazuto ^{[13
]}

Ochi, Hironori ^{[14
]}

Yasuda, Satoshi ^{[15
]}

Toyoda, Hidenori ^{[15
]}

Ogawa, Chikara ^{[16
]}

Nishimura, Takashi ^{[17
]}

Hatanaka, Takeshi ^{[18
]}

Kakizaki, Satoru ^{[19
]}

Shimada, Noritomo ^{[20
]}

Kawata, Kazuhito ^{[21
]}

Naganuma, Atsushi ^{[22
]}

Kosaka, Hisashi ^{[23
]}

Matono, Tomomitsu ^{[24
]}

Kuroda, Hidekatsu ^{[25
]}

Yata, Yutaka ^{[26
]}

Ohama, Hideko ^{[1
]}

Tada, Fujimasa ^{[1
]}

Nouso, Kazuhiro ^{[5
]}

Morishita, Asahiro ^{[6
]}

Tsutsui, Akemi ^{[8
]}

Nagano, Takuya ^{[8
]}

Itokawa, Norio ^{[7
]}

Okubo, Tomomi ^{[7
]}

Arai, Taeang ^{[7
]}

Imai, Michitaka ^{[12
]}

Koizumi, Yohei ^{[4
]}

Nakamura, Shinichiro ^{[3
]}

Iijima, Hiroko ^{[17
]}

Kaibori, Masaki ^{[23
]}

Hiasa, Yoichi ^{[4
]}

机构：

[1] Ehime Prefectural Cent Hosp, Gastroenterol Ctr, Matsuyama, Ehime 7900024, Japan

[2] Gifu Kyoritsu Univ, Dept Nursing, Ogaki, Japan

[3] Japanese Red Cross Himeji Hosp, Dept Internal Med, Himeji, Hyogo, Japan

[4] Ehime Univ, Dept Gastroenterol & Metabol, Grad Sch Med, Toon, Japan

[5] Okayama City Hosp, Dept Hepatol, Okayama, Japan

[6] Kagawa Univ, Dept Gastroenterol & Hepatol, Takamatsu, Kagawa, Japan

[7] Nippon Med Sch, Div Gastroenterol & Hepatol, Dept Internal Med, Tokyo, Japan

[8] Kagawa Prefectural Cent Hosp, Dept Hepatol, Takamatsu, Kagawa, Japan

[9] Asahi Gen Hosp, Dept Gastroenterol, Asahi, Japan

[10] Osaka Med & Pharmaceut Univ, Dept Gastroenterol, Osaka, Japan

[11] Teine Keijinkai Hosp, Ctr Gastroenterol, Sapporo, Hokkaido, Japan

[12] Saiseikai Niigata Hosp, Dept Gastroenterol, Niigata, Japan

[13] Toyama Univ Hosp, Dept Gastroenterol, Toyama, Japan

[14] Japanese Red Cross Matsuyama Hosp, Hepatobiliary Ctr, Matsuyama, Ehime, Japan

[15] Ogaki Municipal Hosp, Dept Gastroenterol & Hepatol, Ogaki, Japan

[16] Japanese Red Cross Takamatsu Hosp, Dept Gastroenterol, Takamatsu, Kagawa, Japan

[17] Hyogo Coll Med, Dept Gastroenterol & Hepatol, Nishinomiya, Hyogo, Japan

[18] Gunma Saiseikai Maebashi Hosp, Dept Gastroenterol, Maebashi, Gunma, Japan

[19] Natl Hosp Org Takasaki Gen Med Ctr, Dept Clin Res, Takasaki, Gumma, Japan

[20] Otakanomori Hosp, Div Gastroenterol & Hepatol, Kashiwa, Chiba, Japan

[21] Hamamatsu Univ, Hepatol Div, Dept Internal Med II, Sch Med, Hamamatsu, Shizuoka, Japan

[22] Natl Hosp Org Takasaki Gen Med Ctr, Dept Gastroenterol, Takasaki, Gumma, Japan

[23] Kansai Med Univ, Dept Surg, Hirakata, Osaka, Japan

[24] St Marys Hosp, Dept Hepatol, Himeji, Hyogo, Japan

[25] Iwate Med Univ, Sch Med, Dept Internal Med, Div Hepatol, Morioka, Iwate, Japan

[26] Hanwa Mem Hosp, Dept Gastroenterol, Osaka, Japan

来源：

HEPATOLOGY RESEARCH | 2023年 / 53卷 / 10期

关键词：

atezolizumab plus bevacizumab; geriatric nutritional risk index; modified albumin-bilirubin grade; nutrition; sarcopenia; MANAGEMENT; GUIDELINES; LENVATINIB; SORAFENIB;

D O I：

10.1111/hepr.13934

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

AimThe present study focused on Geriatric Nutritional Risk Index (GNRI), which is based on bodyweight and serum albumin, and known as an easy-to-use nutritional assessment tool in clinical settings, to elucidate the prognostic predictive ability of GNRI in patients treated with atezolizumab plus bevacizumab (Atez/Bev) for hepatocellular carcinoma (HCC). MethodsA total of 525 HCC patients treated with Atez/Bev, based on their classification of unsuitable status for curative treatments and/or transarterial catheter chemoembolization, were enrolled (Child-Pugh A:B:C = 484:40:1, Barcelona Clinic Liver Cancer stage 0:A:B:C:D = 7:25:192:283:18). Prognosis was evaluated retrospectively using GNRI. ResultsAtez/Bev was used in 338 of the present cohort as first-line systemic chemotherapy (64.4%). Median progression-free survival based on GNRI indicating normal, mild decline, moderate decline, and severe decline was 8.3, 6.7, 5.3, and 2.4 months, respectively, whereas median overall survival was 21.4, 17.0, 11.5. and 7.3 months, respectively (both p < 0.001). The concordance index (c-index) values of GNRI for predicting prognosis (progression-free survival/overall survival) were superior to those of Child-Pugh class and albumin-bilirubin grade (0.574/0.632 vs. 0.527/0.570 vs. 0.565/0.629). As a subanalysis, muscle volume loss was observed in 37.5% of 256 patients with computed tomography data available. Along with GNRI decline, frequency of muscle volume loss became progressively larger (normal vs. mild vs. moderate vs. severe = 17.6% vs. 29.2% vs. 41.2% vs. 57.9%, p < 0.001), and a GNRI value of 97.8 was predictive of its occurrence (AUC 0.715, 95% CI 0.649-0.781; specificity/sensitivity = 0.644/0.688). ConclusionThese findings indicate that GNRI is an effective nutritional prognostic tool for predicting prognosis and muscle volume loss complication in HCC patients treated with Atez/Bev.

引用

页码：1031 / 1042

页数：12

共 50 条

[1] ATEZOLIZUMAB PLUS BEVACIZUMAB THERAPY FOR HEPATOCELLULAR CARCINOMA - GERIATRIC NUTRITIONAL RISK INDEX AS A CONVENIENT PROGNOSTIC EVALUATION TOOL
Hiraoka, Atsushi
Tada, Toshifumi
Ohama, Hideko
Hirooka, Masashi
Tada, Fujimasa
Kariyama, Kazuya
Itobayashi, Ei
Kunihiko, Tsuji
Ishikawa, Toru
Toyoda, Hidenori
Hatanaka, Takeshi
Kakizaki, Satoru
Naganuma, Atsushi
Matono, Tomomitsu
Nouso, Kazuhiro
Kumada, Takashi
HEPATOLOGY, 2023, 78 : S1805 - S1806
[2] Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Persano, Mara
Rimini, Margherita
Tada, Toshifumi
Suda, Goki
Shimose, Shigeo
Kudo, Masatoshi
Cheon, Jaekyung
Finkelmeier, Fabian
Lim, Ho Yeong
Presa Ramos, Jose
Masi, Gianluca
Yoo, Changhoon
Lonardi, Sara
Stefanini, Bernardo
Kumada, Takashi
Sakamoto, Naoya
Iwamoto, Hideki
Aoki, Tomoko
Chon, Hong Jae
Himmelsbach, Vera
Montes, Margarida
Vivaldi, Caterina
Solda, Caterina
Hiraoka, Atsushi
Sho, Takuya
Niizeki, Takashi
Nishida, Naoshi
Steup, Christoph
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Hatanaka, Takeshi
Kakizaki, Satoru
Shimada, Noritomo
Kawata, Kazuhito
Tada, Fujimasa
Ohama, Hideko
Nouso, Kazuhiro
ONCOLOGY, 2023, 101 (05) : 283 - 291
[3] Nutritional status is associated with prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Tada, Toshifumi
Kumada, Takashi
Hiraoka, Atsushi
Kariyama, Kazuya
Tani, Joji
Hirooka, Masashi
Takaguchi, Koichi
Atsukawa, Masanori
Fukunishi, Shinya
Itobayashi, Ei
Tsuji, Kunihiko
Tajiri, Kazuto
Ochi, Hironori
Ishikawa, Toru
Yasuda, Satoshi
Ogawa, Chikara
Toyoda, Hidenori
Hatanaka, Takeshi
Nishimura, Takashi
Kakizaki, Satoru
Kawata, Kazuhito
Shimada, Noritomo
Tada, Fujimasa
Nouso, Kazuhiro
Tsutsui, Akemi
Ohama, Hideko
Morishita, Asahiro
Nagano, Takuya
Itokawa, Norio
Okubo, Tomomi
Arai, Taeang
Kosaka, Hisashi
Imai, Michitaka
Naganuma, Atsushi
Nakamura, Shinichiro
Koizumi, Yohei
Matono, Tomomitsu
Kaibori, Masaki
Iijima, Hiroko
Hiasa, Yoichi
ONCOLOGY, 2023, 101 (04) : 270 - 281
[4] Prognostic value of geriatric nutritional risk index and prognostic nutritional index in hepatocellular carcinoma
Yang, Cheng-Kun
Huang, Ke-Tuan
Qin, Wei
Wu, Qiong-Yuan
Huang, Xin-Lei
Peng, Kai
Lao, Quan
Ye, Xin-Ping
Zhu, Guang-Zhi
Li, Tian-Man
Peng, Tao
CLINICAL NUTRITION ESPEN, 2024, 59 : 355 - 364
[5] Considering nutritional status to improve outcomes of patients treated by atezolizumab-bevacizumab for advanced hepatocellular carcinoma
Allaire, Manon
Avila, Matias A.
LIVER INTERNATIONAL, 2024, 44 (06) : 1276 - 1277
[6] The use of the Geriatric Nutritional Risk Index (GNRI) as a simplified nutritional screening tool
Cereda, Emanuele
Pedrolli, Carlo
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2008, 87 (06): : 1966 - 1967
[7] A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
Watanabe, Yukinobu
Ogawa, Masahiro
Tamura, Yu
Suda, Seiichiro
Kaneko, Masahiro
Kumagawa, Mariko
Hirayama, Midori
Matsumoto, Naoki
Yamamoto, Toshiki
Moriyama, Mitsuhiko
JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS, 2021, 9
[8] Lower Geriatric Nutritional Risk Index and Prognostic Nutritional Index Predict Postoperative Prognosis in Patients with Hepatocellular Carcinoma
Tsukagoshi, Mariko
Araki, Kenichiro
Igarashi, Takamichi
Ishii, Norihiro
Kawai, Shunsuke
Hagiwara, Kei
Hoshino, Kouki
Seki, Takaomi
Okuyama, Takayuki
Fukushima, Ryosuke
Harimoto, Norifumi
Shirabe, Ken
NUTRIENTS, 2024, 16 (07)
[9] The Geriatric Nutritional Risk Index Predicts Tolerability of Lenvatinib in Patients With Hepatocellular Carcinoma
Kinoshita, Akiyoshi
Hagiwara, Noriko
Osawa, Akiyuki
Akasu, Takafumi
Matsumoto, Yoshihiro
Ueda, Kaoru
Saeki, Chisato
Oikawa, Tsunekazu
Koike, Kazuhiko
Saruta, Masayuki
IN VIVO, 2022, 36 (02): : 865 - 873
[10] Geriatric nutritional risk index as a nutritional and survival risk assessment tool in stable outpatients with systolic heart failure
Sargento, L.
Vicente Simoes, A.
Rodrigues, J.
Longo, S.
Lousada, N.
Palma dos Reis, R.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2017, 27 (05) : 430 - 437

← 1 2 3 4 5 →